References
- Miller N. Alcohol and drug disorders. In: Silver JM, Yudofsky SC, Hales RE, editors. Neuropsychiatry of Traumatic Brain Injury. Washington DC: American Psychiatrc Press Inc.; 1994; pp 471–512.
- Hibbard MR, Uysal S, Kepler K, et al. Axis I psychopathology in individuals with traumatic brain injury. Journal of Head Trauma Rehabilitation 1998;13:24–39.
- Bourdon KH, Rae DS, Locke BZ, et al. Estimating the prevalence of mental disorders in US adults from the Epidemiologic Catchment Area Survey. Public Health Reports 1992;107:663–8.
- Schneider U, Altmann A, Baumann M, et al. Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: The first Multicentre Study in Germany. Alcohol & Alcoholism 2001;36:219–23.
- Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. Journal of Addictive Diseases 2002;21:55–64.
- Brady KT, Myrick H, Henderson S, et al. The use of divalproex in alcohol relapse prevention: A pilot study. Drug & Alcohol Dependence 2002;67:323–30.
- Johnson BA, Ait-Daoid N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. [comment]. Lancet 2003;361:1677–85.
- Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: An approach to evaluation and treatment. Seminars in Clinical Neuropsychiatry 2000;5:290–306.
- Koponen S, Taiminen T, Porfin R, et al. Axis I and II psychiatric disorders after traumatic brain injury: A 30-year follow-up study. American Journal of Psychiatry 2002;159:1315–21.
- Palmer A, Marion D, Botscheller M, et al. Increased transmitter amino acid concentration in human ventricular CSF after brain trauma. Neuroreport 1994;6:153–6.
- O'Dell DM, Hamm RJ. Chronic post-injury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury. Journal of Neurosurgery 1995; 83:878–83.
- Reeves TM, Lyeth BG, Phillips LL, et al. The effects of traumatic brain injury on inhibition in the hippocampus and dentate gyrus. Brain Research 1997;757:119–32.
- Erb DE, Povlishock JT. Neuroplasticity following traumatic brain injury: A study of GABAergic terminal loss and recovery in the cat dorsal lateral vestibular nucleus. Experimental Brain Research 1991;83:253–67.
- Petty F. GABA and mood disorders: A brief review and hypothesis. Journal of Affective Disorders 1995;34:275–81.
- Oruc L, Verheyen GR, Furac I, et al. Positive association between the GABRA5 gene and unipolar recurrent major depression. Neuropsychobiology 1997;36:62–4.
- Papadimitriou GN, Dikeos DG, Karadima G, et al. Association between the GABA(A) receptor alpha5 subunit gene locus (GABRA5) and bipolar affective disorder. American Journal of Medical Genetics 1998;81:73–80.
- Perucca E. Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 2002;16:695–714.
- White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40 (Suppl 5):52–10.
- Kawata Y, Okada M, Murakami T, et al. Pharmacological discrimination between effects of carbamazepine on hippo-campal basal, Ca(2+)- and K(+)-evoked serotonin release. British Journal of Pharmacology 2001;133:557–67.
- Ichikawa J, Meltzer HY. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. European Journal of Pharmacology 1999; 380:R1–3.
- Corrigan JD. Substance abuse as a mediating factor in outcome from traumatic brain injury. Archives of Physical Medicine & Rehabilitation 1995;76:302–9.